Intrust Bank NA now owns 3,146 shares of the medical research company’s stock valued at $1,185,000 after buying an additional 33 shares in the last quarter. Intrust Bank NA grew its holdings in Charles River Laboratories International by 1.1% during the 4th quarter. Argent Trust Co now owns 1,266 shares of the medical research company’s stock valued at $477,000 after acquiring an additional 30 shares during the period. Argent Trust Co raised its stake in Charles River Laboratories International by 2.4% in the 4th quarter. Insiders own 1.10% of the company’s stock.Ī number of institutional investors have recently made changes to their positions in the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Following the sale, the director now directly owns 4,677 shares in the company, valued at approximately $1,080,199.92. The stock was sold at an average price of $230.96, for a total transaction of $41,110.88. In other news, Director George Massaro sold 178 shares of Charles River Laboratories International stock in a transaction on Monday, May 9th. The firm has a market cap of $11.15 billion, a price-to-earnings ratio of 26.74, a PEG ratio of 1.35 and a beta of 1.27. The firm has a 50 day moving average price of $252.12 and a two-hundred day moving average price of $298.94. Charles River Laboratories International has a 52-week low of $214.67 and a 52-week high of $460.21. The company has a debt-to-equity ratio of 1.02, a quick ratio of 1.12 and a current ratio of 1.34. According to, the company currently has an average rating of “Buy” and an average target price of $386.17.Ĭharles River Laboratories International stock opened at $219.50 on Monday. Four equities research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. Finally, Citigroup raised shares of Charles River Laboratories International from a “neutral” rating to a “buy” rating and set a $400.00 price objective for the company in a research report on Thursday, February 17th.
Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Charles River Laboratories International from $409.00 to $350.00 and set a “buy” rating for the company in a research report on Thursday, February 17th. Morgan Stanley reduced their price objective on shares of Charles River Laboratories International from $465.00 to $430.00 and set an “overweight” rating for the company in a research report on Thursday, February 17th. They noted that the move was a valuation call.
They set a “neutral” rating for the company. Guggenheim started coverage on shares of Charles River Laboratories International in a report on Monday, May 23rd. Wells Fargo & Company lowered their price target on shares of Charles River Laboratories International from $390.00 to $325.00 and set an “overweight” rating for the company in a report on Monday, April 25th. Other research analysts have also issued research reports about the stock.